Free Trial

Bone Biologics (BBLG) Competitors

Bone Biologics logo
$1.01 +0.05 (+5.20%)
As of 01/21/2025 04:00 PM Eastern

BBLG vs. BTCY, AEMD, CHEK, ICU, POAI, NURO, CUTR, MHUA, ALUR, and STRR

Should you be buying Bone Biologics stock or one of its competitors? The main competitors of Bone Biologics include Biotricity (BTCY), Aethlon Medical (AEMD), Check-Cap (CHEK), SeaStar Medical (ICU), Predictive Oncology (POAI), NeuroMetrix (NURO), Cutera (CUTR), Meihua International Medical Technologies (MHUA), Allurion Technologies (ALUR), and Star Equity (STRR). These companies are all part of the "medical equipment" industry.

Bone Biologics vs.

Bone Biologics (NASDAQ:BBLG) and Biotricity (NASDAQ:BTCY) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, community ranking, risk, institutional ownership, profitability, valuation, earnings, media sentiment and analyst recommendations.

Bone Biologics has higher earnings, but lower revenue than Biotricity.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Bone BiologicsN/AN/A-$8.95MN/AN/A
Biotricity$12.06M0.71-$14.09M-$1.37-0.26

Bone Biologics and Biotricity both received 0 outperform votes by MarketBeat users.

CompanyUnderperformOutperform
Bone BiologicsN/AN/A
BiotricityOutperform Votes
No Votes
Underperform Votes
2
100.00%

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Bone Biologics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Biotricity
0 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00

34.3% of Bone Biologics shares are owned by institutional investors. Comparatively, 3.9% of Biotricity shares are owned by institutional investors. 7.5% of Bone Biologics shares are owned by company insiders. Comparatively, 10.1% of Biotricity shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Biotricity had 1 more articles in the media than Bone Biologics. MarketBeat recorded 1 mentions for Biotricity and 0 mentions for Bone Biologics. Bone Biologics' average media sentiment score of 0.00 equaled Biotricity'saverage media sentiment score.

Company Overall Sentiment
Bone Biologics Neutral
Biotricity Neutral

Bone Biologics has a net margin of 0.00% compared to Biotricity's net margin of -97.05%. Biotricity's return on equity of 0.00% beat Bone Biologics' return on equity.

Company Net Margins Return on Equity Return on Assets
Bone BiologicsN/A -124.71% -111.64%
Biotricity -97.05%N/A -221.26%

Bone Biologics has a beta of 0.49, suggesting that its share price is 51% less volatile than the S&P 500. Comparatively, Biotricity has a beta of 1.08, suggesting that its share price is 8% more volatile than the S&P 500.

Summary

Biotricity beats Bone Biologics on 6 of the 10 factors compared between the two stocks.

Get Bone Biologics News Delivered to You Automatically

Sign up to receive the latest news and ratings for BBLG and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

BBLG vs. The Competition

MetricBone BiologicsSurgical appliances & supplies IndustryMedical SectorNASDAQ Exchange
Market Cap$2.39M$10.12B$5.39B$9.13B
Dividend YieldN/A1.36%5.37%4.00%
P/E RatioN/A18.3288.9117.53
Price / SalesN/A27.601,290.81137.24
Price / CashN/A24.6436.6032.90
Price / Book0.145.834.964.69
Net Income-$8.95M$177.36M$117.89M$224.57M
7 Day Performance4.36%2.72%1.68%1.69%
1 Month PerformanceN/A7.84%3.63%5.34%
1 Year Performance-73.21%-4.35%26.16%21.47%

Bone Biologics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
BBLG
Bone Biologics
N/A$1.01
+5.2%
N/A-68.9%$2.39MN/A0.002Gap Up
BTCY
Biotricity
N/A$0.38
-12.8%
N/A-66.0%$9.21M$12.06M-0.2740Gap Down
AEMD
Aethlon Medical
1.8165 of 5 stars
$0.64
-4.8%
$7.00
+1,002.4%
-65.4%$8.87M$570,000.00-0.2310Analyst Forecast
CHEK
Check-Cap
0.2842 of 5 stars
$1.50
-2.0%
N/A-45.0%$8.78MN/A-0.5080Analyst Forecast
News Coverage
Positive News
ICU
SeaStar Medical
0.1997 of 5 stars
$1.95
-2.0%
N/A-89.5%$8.70M$68,000.00-0.172
POAI
Predictive Oncology
1.9275 of 5 stars
$1.28
-5.9%
$3.00
+134.4%
-56.9%$8.53M$1.48M-0.4230
NURO
NeuroMetrix
0.4539 of 5 stars
$4.01
+1.0%
N/A+35.3%$8.19M$3.77M-0.8720
CUTR
Cutera
1.3828 of 5 stars
$0.40
-12.7%
$3.00
+647.4%
-82.2%$8.10M$155.21M-0.06460Analyst Forecast
Positive News
Gap Down
MHUA
Meihua International Medical Technologies
1.0187 of 5 stars
$0.32
-1.4%
N/A-64.7%$7.97M$94.25M0.00620Positive News
ALUR
Allurion Technologies
3.3911 of 5 stars
$2.97
-22.4%
$71.88
+2,323.3%
-96.2%$7.69M$34.75M-6.18501News Coverage
STRR
Star Equity
N/A$2.19
-1.4%
N/A-54.9%$7.05M$45.78M-0.85460Positive News

Related Companies and Tools


This page (NASDAQ:BBLG) was last updated on 1/22/2025 by MarketBeat.com Staff
From Our Partners